Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

renal cell carcinoma

This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most ... Bavencio is also approved for the

Latest news

  • World Castleman Disease Day World Castleman Disease Day

    Through their existing portfolio, which supports patients with iMCD, neuroblastoma, renal cell carcinoma (RCC) and oral mucositis (dryness of the mouth and throat) as a common side effect to anticancer therapy,

  • Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

    The partners had been testing Bavencio (avelumab) in untreated, advanced squamous cell carcinoma of the head and neck. ... Merck KGaA/Pfizer’s drug then picked up an approval in first-line, advanced renal cell carcinoma (RCC) last year, the most common

  • BMS scores first oesophageal cancer nod for Opdivo in Japan BMS scores first oesophageal cancer nod for Opdivo in Japan

    with unresectable advanced or recurrent oesophageal squamous cell carcinoma (ESCC), which did not respond to or was intolerant to combination therapy with fluoropyrimidine and platinum-based drugs. ... BMS’ drug has already  received approval for the

  • BMS unveils long-term results for Opdivo in kidney cancer BMS unveils long-term results for Opdivo in kidney cancer

    Results include updated data for Opdivo with or without Yervoy. Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 ... line non-small cell lung cancer indication.

  • Revenue growth at Ipsen numbs pain of palovarotene calamity Revenue growth at Ipsen numbs pain of palovarotene calamity

    The company is waiting for phase 3 results for Cabometyx in combination with Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in first-line renal cell carcinoma, which could add further momentum ... It also has data due in the coming months for

More from news
Approximately 8 fully matching, plus 150 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in

  • Charting a course for expansion Charting a course for expansion

    Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Deal Watch December 2015 Deal Watch December 2015

    510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Communiqué Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Quick links

Infographics

Multimedia